GRI Bio (GRI) Projected to Post Earnings on Friday

GRI Bio (NASDAQ:GRI) is expected to be releasing its Q3 2026 results on Friday, November 13th. Analysts expect GRI Bio to post earnings of ($0.84) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

GRI Bio (NASDAQ:GRI) last issued its earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.28. On average, analysts expect GRI Bio to post ($3.75) EPS for the current fiscal year and ($2.00) EPS for the next fiscal year.

GRI Bio Price Performance

GRI opened at $1.89 on Wednesday. GRI Bio has a 12-month low of $1.36 and a 12-month high of $64.12. The business’s fifty day simple moving average is $1.78 and its 200-day simple moving average is $2.11.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on GRI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a research note on Thursday, October 15th. HC Wainwright reissued a “buy” rating on shares of GRI Bio in a research report on Tuesday, October 13th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GRI Bio has a consensus rating of “Hold” and a consensus price target of $21.00.

About GRI Bio

GRI Bio, Inc. (NASDAQ: GRI) is a clinical-stage biotechnology company focused on developing therapies that modulate natural killer T (NKT) cells. NKT cells are immune cells involved in regulating inflammation and immune responses, and the company is researching their potential role in autoimmune, inflammatory, and fibrotic diseases. GRI Bio’s lead product candidate is GRI-0621, an orally administered small-molecule inhibitor designed to selectively modulate type I NKT cells. The company has been evaluating GRI-0621 as a potential treatment for idiopathic pulmonary fibrosis, a progressive lung disease characterized by scarring and impaired respiratory function.